---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-103787"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:24:11.367071+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Intellia appoints Bill Chase to board; Caroline Dorsa to retire June 15, 2023

## Summary
- Bill Chase, former AbbVie CFO, appointed as Class III director, effective April 14, 2023.
- Caroline Dorsa to retire from board on June 15, 2023, after being appointed chair of Biogen's board.
- Chase will serve on audit committee and succeed Dorsa as audit committee chair.
- Chase received grant of 14,931 stock options and 10,483 RSUs under director compensation program.

## SEC filing metadata
- accession: 0001193125-23-103787
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312523103787/0001193125-23-103787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312523103787/d485270d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-103787
- JSON: https://secwatch.observer/filing/0001193125-23-103787.json
- Plain text: https://secwatch.observer/filing/0001193125-23-103787.txt

## Key facts
- Executive change
  Bill Chase was appointed as Class III Director at Intellia Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: the Board appointed Bill Chase, M.B.A., as a Class III director, with a term expiring at the 2025 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312523103787/0001193125-23-103787-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.